Muscarinic agonists as enhancers of cognitive flexibility
View Patent ↗Methods and compositions for treating a mental condition in a subject in need thereof, includes administering to a subject in need thereof an effective amount of a CDD-102A compound [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine], or a pharmaceutically acceptable salt or hydrate thereof pharmaceutically acceptable salt or hydrate thereof.
1. A method of improving a cognitive flexibility function in a human subject having a need thereof, comprising the steps of:
administering to the subject a composition that includes a therapeutically effective amount of at least one M1 agonist compound without substantially producing M2, M3, M4 and/or M5 subtype receptor agonist activity;
wherein the M1 agonist compound is [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] (CDD-0102), or a pharmaceutically acceptable salt or hydrate thereof; and
wherein the subject does not have a cholinergic deficit, and does have cognitive deficits not associated with a neurodegenerative disorder; and,
improving the cognitive flexibility function in the subject.
2. The method of claim 1 , wherein the CDD-0102 compound, or a pharmaceutically acceptable salt or hydrate thereof, is administered to the subject in a dose of
about 0.01 mg/kg to about 0.3 mg/kg.
3. The method of claim 2 , wherein the CDD-0102 compound or a pharmaceutically acceptable salt or hydrate thereof, is administered to the subject in a dose between about 0.01 mg/kg and about 0.3 mg/kg, to thereby effect improved behavioral flexibility in the subject.
4. The method of claim 1 , wherein the CDD-0102 compound, or a pharmaceutically acceptable salt or hydrate thereof, is administered to the subject in at least one member selected from the group consisting of a single daily dose, multiple daily doses, two daily doses, three daily doses, four daily doses and five daily doses.
5. The method of claim wherein the CDD-0102 compound, or a pharmaceutically acceptable salt or hydrate thereof, is orally administered to the subject.
6. The method of claim 1 , wherein the subject has one or more neuropsychiatric diseases selected from: dysexecutive syndrome of schizophrenia; Fragile X disease; chronic alcoholism; traumatic brain injury; autism spectrum disorders; attention-deficit hyperactivity disorders; and post-traumatic stress disorder.
7. The method of claim 1 , wherein the subject is a human child.
8. The method of claim 1 , wherein the subject is a human adult.
9. The method of claim 1 , wherein the compound is formulated in a nutraceutical composition and is administered orally.
10. The method of claim 1 , wherein the administration is chronic.